Clinical Trials
23 trialsNCT05579366 2026-06-03
RAINFOL-01
Genmab
Phase 1/2 Recruiting
NCT01366144 2026-04-13
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04644068 2026-02-19
PETRA
AstraZeneca
Phase 1/2 Active not recruiting
NCT06400472 2026-01-14
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Recruiting
NCT04954599 2025-10-07
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Maastricht University Medical Center
Phase 1/2 Recruiting
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT03717415 2024-12-27
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
Deciphera Pharmaceuticals, LLC
Phase 1/2 Terminated
NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT02897375 2023-10-10
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
Emory University
Phase 1 Completed
NCT01618136 2023-06-18
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Eisai Inc.
Phase 1/2 Completed
NCT03134638 2021-03-09
A Study of SY-1365 in Adult Patients With Advanced Solid Tumors
Syros Pharmaceuticals
Phase 1 Terminated
NCT02476955 2020-09-30
Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Terminated
NCT02658214 2020-08-20
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
AstraZeneca
Phase 1 Completed
NCT01237067 2019-12-17
Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01445418 2019-10-22
AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02069158 2019-05-21
IOSI-NDU-001
Oncology Institute of Southern Switzerland
Phase 1 Completed
NCT02418624 2019-01-16
REVIVAL
The Netherlands Cancer Institute
Phase 1 Completed
NCT03032614 2017-10-10
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
The University of Texas Health Science Center at San Antonio
Phase 2 Withdrawn
NCT02033551 2016-09-27
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors
AbbVie
Phase 1 Completed
NCT00117442 2013-05-13
A Study of Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole Blood
Amgen
Phase 2 Completed
NCT00316407 2011-02-18
Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients
Swedish Medical Center
Phase 1/2 Completed